paclitaxel-eluting stent

Clinical Trial Update

Two-Year Results of IMPERIAL: First-Ever Randomized Study of Eluvia and Zilver PTX in Femoropopliteal Artery Lesions

12/09/2019

Vascular Disease Management talks with IMPERIAL trial co-principal investigator William A. Gray, MD, FACC, FSCAI, System Chief, Division of Cardiovascular Disease; President, Lankenau Heart Institute, Main Line Health, Wynnewood, Pennsylvania.

Vascular Disease Management...

12/09/2019

Vascular Disease Management

FDA Panel

Accepting the Risk of Treatment with Drug-Coated Balloons

06/22/2019

Frank J. Veith , MD;

VDM talks with Frank J. Veith, MD, Professor of Surgery, New York University-Langone Medical Center and The Cleveland Clinic Lerner College of Medicine; The William J. von Liebig Chair in Vascular Surgery; Cleveland, Ohio and New York, New...

VDM talks with Frank J. Veith,...

06/22/2019

Vascular Disease Management

Editor's Corner

A Potential Danger Signal Associated With Paclitaxel-Eluting Devices

01/21/2019

Craig M. Walker , MD, FACC, FACP, FSCAI, FCCP;

Dr. Walker comments on a hotly debated meta-analysis by Katsanos and colleagues on the risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg.

Dr. Walker comments on a hotly...

01/21/2019

Vascular Disease Management

Clinical Images

Saphenous Vein Graft Aneurysm 10 Years After Paclitaxel-Eluting Stent Implantation

04/25/2017

Antonio Colombo , MD;

Akihito Tanaka , MD;

Richard J. Jabbour , MD;

Francesco Giannini , MD;

Azeem Latib , MD, BCh, MBBCh;

A patient underwent paclitaxel-eluting implantation for a saphenous vein graft stenosis. Follow-up angiogram at 8-months demonstrated no restenosis with multifocal peristent contrast staining. After 10 years, a saphenous vein graft aneurysm...

A patient underwent...

04/25/2017

Journal of Invasive Cardiology